If you're an investor focused on growth, you may have spent a fair share of your time at least watching Nvidia (NASDAQ: NVDA) stock in recent times -- even if you haven't jumped in to invest in this high-flyer. Nvidia dominates the artificial intelligence (AI) chip market, and that's helped the company deliver triple-digit gains in revenue and profit. The stock has followed, climbing 126% so far this year.

But Nvidia isn't the only player generating big returns for investors. In fact, an up-and-coming biotech stock actually has been crushing Nvidia in recent months. This stock has advanced 247% since the start of the year. And this past week, the stock soared more than 28% in one trading session after the company announced one of its product candidates would begin a late-stage clinical trial.

Let's find out more about this stock that's beating Nvidia -- and whether it's a buy right now for growth investors.

Continue reading

Source Fool.com